Patients undergo first doses of GE HealthCare's PET radiotracer Flyrcado (flurpiridaz F 18) injection at early adopter sites ...

GE HealthCare (GEHC) has delivered the first patient doses of Flyrcado or flurpiridaz F 18 njection, a first-of-its-kind unit dose positron ...

GE HealthCare (Nasdaq: GEHC) has delivered the first patient doses of Flyrcado™ (flurpiridaz F 18) injection, a first-of-its-kind unit dose positron emission tomography myocardial perfusion ...

GE HealthCare has delivered the initial subject doses of Flyrcado (flurpiridaz F 18) injection, for coronary artery disease ...

The company announced the planned launch of Flyrcado, a radiopharmaceutical product for myocardial perfusion imaging, in April 2025. It is expected to generate $30 million in revenue for 2025 and ...

based UW Health are the first U.S. healthcare organizations to use GE Healthcare's new PET radiotracer, Flyrcado. The radiopharmaceutical is a positron emission tomography myocardial perfusion ...

February 13, 2025GE HealthCare Technologies Inc. beats earnings expectations. Reported EPS is $1.45, expectations were $1.26.

Good day, and thank you for standing by. Welcome to the GE HealthCare fourth quarter and full year 2024 earnings conference call. (Operator Instructions) Please be advised this conference is being ...

For example, our cath lab Allia IGS Pulse is outperforming our expectations and we're on track to launch Flyrcado in the near term. We continue to advance our leadership position in AI.